Close Menu

GSK

NEW YORK (GenomeWeb News) – German firm Alacris Theranostics today announced a deal with GlaxoSmithKline for the application of Alacris' Modcell System for drug stratification.

Mirna Therapeutics this week announced that it has closed a Series C round of financing, raising $34.5 million in what is the microRNA therapeutics field's biggest single round of private investment.

NEW YORK (GenomeWeb News) – Response Genetics has raised $8.8 million through a private placement of its stock with GlaxoSmithKline and an existing "significant" stockholder, the firm said today.

With Positive Survival Data, Genentech Crossing over EMILIA Patients on Lapatinib/Capecitabine Combo to T-DM1

Alnylam Pharmaceuticals this week announced that it has received a $3.2 million milestone payment from GlaxoSmithKline related to the companies' collaboration on influenza vaccine production.

NEW YORK (GenomeWeb News) – The UK lab that is currently serving as an anti-doping testing facility for the 2012 Olympic and Paralympic games will be turned into a research center that will focus on phenomics-based disease studies.

NEW YORK (GenomeWeb News) – KineMed today announced an agreement with GlaxoSmithKline for the use of KineMed's biomarker discovery platform in therapeutic areas of interest for the drug manufacturer.

The American Society of Clinical Oncology held its annual meeting June 1-5 in Chicago. The following are abstracts presented at the meeting focused on pharmacogenomically guided treatment strategies.

Pages

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.